Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:356538.
doi: 10.1155/2011/356538. Epub 2011 Nov 30.

Dilation of malignant strictures in endoscopic ultrasound staging of esophageal cancer and metastatic spread of disease

Shawn M Hancock  1 , Deepak V Gopal, Terrence J Frick, Patrick R Pfau
Affiliations

Dilation of malignant strictures in endoscopic ultrasound staging of esophageal cancer and metastatic spread of disease

Shawn M Hancock et al. Diagn Ther Endosc. 2011.

Abstract

Background. Dilation of malignant strictures in endoscopic ultrasound (EUS) staging of esophageal cancer is safe, but no data exists regarding the subsequent development of metastases. Aim. Compare the rates of metastases in esophageal cancer patients undergoing EUS staging who require esophageal dilation in order to pass the echoendoscope versus those who do not. Methods. We reviewed consecutive patients referred for EUS staging of esophageal cancer. We evaluated whether dilation was necessary in order to pass the echoendoscope, and for the subsequent development of metastases after EUS at various time intervals. Results. Among all patients with similar stage (locally advanced disease, defined as T3, N0, M0 or T1-3, N1, M0), there was no difference between the dilated and nondilated groups in the rates of metastases at 3 months (14% versus 10%), P = 1.0, 6 months (28% versus 20%), P = 0.69, 12 months (43% versus 40%), P = 1.0, or ever during a mean followup of 15 months (71% versus 55%), P = 0.48. Conclusions. Dilation of malignant strictures for EUS staging of esophageal cancer does not appear to lead to higher rates of distant metastases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Development of metastases at any time during a mean followup of 20 months among all patients without metastases present at the time of staging EUS.
Figure 2
Figure 2
Development of metastases at various time intervals after EUS among patients with similar staging-locally advanced disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. van Dam J, Rice TW, Catalano MF, Kirby T, Sivak MV. High-grade malignant stricture is predictive of esophageal tumor stage: risks of endosonographic evaluation. Cancer. 1993;71(10):2910–2917. - PubMed
    1. Kallimanis GE, Gupta PK, Al-Kawas FH, et al. Endoscopic ultrasound for staging esophageal cancer, with or without dilation, is clinically important and safe. Gastrointestinal Endoscopy. 1995;41(6):540–546. - PubMed
    1. Pfau PR, Ginsberg GG, Lew RJ, Faigel DO, Smith DB, Kochman ML. Esophageal dilation for endosonographic evaluation of malignant esophageal strictures is safe and effective. American Journal of Gastroenterology. 2000;95(10):2813–2815. - PubMed
    1. Wallace MB, Hawes RH, Sahai AV, van Velse A, Hoffman BJ. Dilation of malignant esophageal stenosis to allow EUS guided fine-needle aspiration: safety and effect on patient management. Gastrointestinal Endoscopy. 2000;51(3):309–313. - PubMed
    1. Pfau PR, Perlman SB, Stanko P, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointestinal Endoscopy. 2007;65(3):377–384. - PubMed

LinkOut - more resources